Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Pathological Mechanisms and Therapeutic Targets for Trigeminal Neuropathic Pain.

Bista P, Imlach WL.

Medicines (Basel). 2019 Aug 22;6(3). pii: E91. doi: 10.3390/medicines6030091. Review.

2.

Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord.

Winters BL, Rawling T, Vandenberg RJ, Christie MJ, Bhola RF, Imlach WL.

Br J Pharmacol. 2018 Jun;175(12):2337-2347. doi: 10.1111/bph.14189. Epub 2018 Apr 14.

3.

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission.

Yarwood RE, Imlach WL, Lieu T, Veldhuis NA, Jensen DD, Klein Herenbrink C, Aurelio L, Cai Z, Christie MJ, Poole DP, Porter CJH, McLean P, Hicks GA, Geppetti P, Halls ML, Canals M, Bunnett NW.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12309-12314. doi: 10.1073/pnas.1706656114. Epub 2017 Oct 30.

4.

Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.

Jensen DD, Lieu T, Halls ML, Veldhuis NA, Imlach WL, Mai QN, Poole DP, Quach T, Aurelio L, Conner J, Herenbrink CK, Barlow N, Simpson JS, Scanlon MJ, Graham B, McCluskey A, Robinson PJ, Escriou V, Nassini R, Materazzi S, Geppetti P, Hicks GA, Christie MJ, Porter CJH, Canals M, Bunnett NW.

Sci Transl Med. 2017 May 31;9(392). pii: eaal3447. doi: 10.1126/scitranslmed.aal3447.

5.

Corrigendum: Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.

Deuis JR, Dekan Z, Wingerd JS, Smith JJ, Munasinghe NR, Bhola RF, Imlach WL, Herzig V, Armstrong DA, Rosengren KJ, Bosmans F, Waxman SG, Dib-Hajj SD, Escoubas P, Minett MS, Christie MJ, King GF, Alewood PF, Lewis RJ, Wood JN, Vetter I.

Sci Rep. 2017 May 26;7:46816. doi: 10.1038/srep46816. No abstract available.

6.

Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.

Deuis JR, Dekan Z, Wingerd JS, Smith JJ, Munasinghe NR, Bhola RF, Imlach WL, Herzig V, Armstrong DA, Rosengren KJ, Bosmans F, Waxman SG, Dib-Hajj SD, Escoubas P, Minett MS, Christie MJ, King GF, Alewood PF, Lewis RJ, Wood JN, Vetter I.

Sci Rep. 2017 Jan 20;7:40883. doi: 10.1038/srep40883. Erratum in: Sci Rep. 2017 May 26;7:46816.

7.

New approaches to target glycinergic neurotransmission for the treatment of chronic pain.

Imlach WL.

Pharmacol Res. 2017 Feb;116:93-99. doi: 10.1016/j.phrs.2016.12.019. Epub 2016 Dec 14. Review.

PMID:
27988386
8.

Glycinergic dysfunction in a subpopulation of dorsal horn interneurons in a rat model of neuropathic pain.

Imlach WL, Bhola RF, Mohammadi SA, Christie MJ.

Sci Rep. 2016 Nov 14;6:37104. doi: 10.1038/srep37104.

9.

A Positive Allosteric Modulator of the Adenosine A1 Receptor Selectively Inhibits Primary Afferent Synaptic Transmission in a Neuropathic Pain Model.

Imlach WL, Bhola RF, May LT, Christopoulos A, Christie MJ.

Mol Pharmacol. 2015 Sep;88(3):460-8. doi: 10.1124/mol.115.099499. Epub 2015 Jun 23.

PMID:
26104547
10.

Glycine transport inhibitors for the treatment of pain.

Vandenberg RJ, Ryan RM, Carland JE, Imlach WL, Christie MJ.

Trends Pharmacol Sci. 2014 Aug;35(8):423-30. doi: 10.1016/j.tips.2014.05.006. Epub 2014 Jun 21. Review.

PMID:
24962068
11.

Miniature neurotransmission regulates Drosophila synaptic structural maturation.

Choi BJ, Imlach WL, Jiao W, Wolfram V, Wu Y, Grbic M, Cela C, Baines RA, Nitabach MN, McCabe BD.

Neuron. 2014 May 7;82(3):618-34. doi: 10.1016/j.neuron.2014.03.012.

12.

An SMN-dependent U12 splicing event essential for motor circuit function.

Lotti F, Imlach WL, Saieva L, Beck ES, Hao le T, Li DK, Jiao W, Mentis GZ, Beattie CE, McCabe BD, Pellizzoni L.

Cell. 2012 Oct 12;151(2):440-54. doi: 10.1016/j.cell.2012.09.012.

13.

SMN is required for sensory-motor circuit function in Drosophila.

Imlach WL, Beck ES, Choi BJ, Lotti F, Pellizzoni L, McCabe BD.

Cell. 2012 Oct 12;151(2):427-39. doi: 10.1016/j.cell.2012.09.011.

14.

Regulation of Fasciclin II and synaptic terminal development by the splicing factor beag.

Beck ES, Gasque G, Imlach WL, Jiao W, Jiwon Choi B, Wu PS, Kraushar ML, McCabe BD.

J Neurosci. 2012 May 16;32(20):7058-73. doi: 10.1523/JNEUROSCI.3717-11.2012.

15.

Mechanism of action of lolitrem B, a fungal endophyte derived toxin that inhibits BK large conductance Ca²+-activated K+ channels.

Imlach WL, Finch SC, Zhang Y, Dunlop J, Dalziel JE.

Toxicon. 2011 Apr;57(5):686-94. doi: 10.1016/j.toxicon.2011.01.013. Epub 2011 Feb 12.

PMID:
21300077
16.

A role for BK channels in heart rate regulation in rodents.

Imlach WL, Finch SC, Miller JH, Meredith AL, Dalziel JE.

PLoS One. 2010 Jan 14;5(1):e8698. doi: 10.1371/journal.pone.0008698.

17.

Structural determinants of lolitrems for inhibition of BK large conductance Ca2+-activated K+ channels.

Imlach WL, Finch SC, Dunlop J, Dalziel JE.

Eur J Pharmacol. 2009 Mar 1;605(1-3):36-45. doi: 10.1016/j.ejphar.2008.12.031. Epub 2009 Jan 10.

PMID:
19210977
18.

The molecular mechanism of "ryegrass staggers," a neurological disorder of K+ channels.

Imlach WL, Finch SC, Dunlop J, Meredith AL, Aldrich RW, Dalziel JE.

J Pharmacol Exp Ther. 2008 Dec;327(3):657-64. doi: 10.1124/jpet.108.143933. Epub 2008 Sep 18.

PMID:
18801945

Supplemental Content

Loading ...
Support Center